Capstone Investment Advisors
REGN icon

Capstone Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capstone Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Buy
500
+200
+67% +$153K ﹤0.01% 1262
2025
Q4 		$232K Sell
300
-100
-25% -$67.9K ﹤0.01% 1459
2025
Q3 		$225K Buy
+400
New +$226K ﹤0.01% 1771
2025
Q2 		– Sell
-500
Closed -$317K – 1714
2025
Q1 		$317K Sell
500
-2,000
-80% -$1.38M ﹤0.01% 1178
2024
Q4 		$1.78M Hold
2,500
– – ﹤0.01% 880
2024
Q3 		$2.63M Buy
2,500
+400
+19% +$445K 0.01% 646
2024
Q2 		$2.21M Buy
2,100
+1,300
+163% +$1.26M 0.01% 684
2024
Q1 		$770K Sell
800
-1,400
-64% -$1.33M ﹤0.01% 1299
2023
Q4 		$1.93M Buy
2,200
+700
+47% +$576K 0.01% 813
2023
Q3 		$1.23M Buy
1,500
+100
+7% +$78.6K 0.01% 910
2023
Q2 		$1.01M Hold
1,400
– – 0.01% 873
2023
Q1 		$1.15M Sell
1,400
-700
-33% -$528K 0.01% 748
2022
Q4 		$1.52M Hold
2,100
– – 0.01% 801
2022
Q3 		$1.45M Buy
2,100
+200
+11% +$126K 0.01% 889
2022
Q2 		$1.12M Sell
1,900
-3,000
-61% -$1.95M 0.01% 963
2022
Q1 		$3.42M Sell
4,900
-11,200
-70% -$7.09M 0.01% 842
2021
Q4 		$10.2M Sell
16,100
-1,900
-11% -$1.17M 0.02% 595
2021
Q3 		$10.9M Buy
18,000
+4,900
+37% +$3.04M 0.02% 596
2021
Q2 		$7.32M Buy
13,100
+3,200
+32% +$1.62M 0.02% 621
2021
Q1 		$4.68M Buy
9,900
+3,000
+43% +$1.46M 0.01% 666
2020
Q4 		$3.33M Sell
6,900
-1,400
-17% -$756K 0.01% 728
2020
Q3 		$4.65M Buy
8,300
+4,900
+144% +$2.97M 0.02% 534
2020
Q2 		$2.12M Sell
3,400
-600
-15% -$341K 0.01% 699
2020
Q1 		$1.95M Sell
4,000
-24,700
-86% -$10.2M 0.03% 528
2019
Q4 		$10.8M Sell
28,700
-4,500
-14% -$1.51M 0.06% 348
2019
Q3 		$9.21M Sell
33,200
-8,700
-21% -$2.57M 0.06% 300
2019
Q2 		$13.1M Buy
41,900
+9,400
+29% +$3.13M 0.09% 224
2019
Q1 		$13.3M Buy
32,500
+31,600
+3,511% +$13M 0.12% 168
2018
Q4 		$336K Buy
900
+600
+200% +$220K ﹤0.01% 909
2018
Q3 		$121K Buy
+300
New +$114K ﹤0.01% 1111

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capstone Investment Advisors's REGN Position: Q1 2026 in Review

Capstone Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 511 shares — an estimated $391K sold.

Capstone Investment Advisors first reported a position in REGN in Q3 2015 and held it in 25 quarters. The position peaked at $11.9M in Q4 2020. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Capstone Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 511 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $391K.
  • Capstone Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 25 quarters.
  • Capstone Investment Advisors's Regeneron Pharmaceuticals position peaked at $11.9M in Q4 2020.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.